Could A Type 1 Diabetes Immunotherapy Be In Reach?
Executive Summary
Promising data from the likes of Provention Bio and Diamyd Medical suggest that treatment for the autoimmune disorder type 1 diabetes could soon move beyond insulin.
You may also be interested in...
EMA Accepts First Diabetes Drug Onto PRIME
Provention Bio’s teplizumab, a potentially game-changing treatment for preventing or delaying type 1 diabetes, is one of three investigational products to be newly accepted onto the European Medicines Agency’s popular priority medicines scheme.
GSK & Tolerx suffer Phase III otelixizumab setback
Targeting CD3 to treat type 1 diabetes has once again been called into question as GSK and Tolerx revealed that the Phase III DEFEND-1 study of otelixzimuab did not meet its primary endpoint in patients with new-onset autoimmune type 1 diabetes. The partners have suspended new recruitment and dosing in the DEFEND-2 study pending review of the DEFEND-1 results. Last autumn, MacroGenics and partner Eli Lilly announced that their anti-CD3 mAb failed to show efficacy in a pivotal Phase II/III trial in type 1 diabetes patients missing the same primary endpoint.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.